Alwakeel Mahmoud, Obeidat Mohammed, Nanah Abdelrahman, Abdeljaleel Fatima, Wang Xiaofeng, Fadell Francois
Department of Pulmonary & Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Internal Medicine, Fairview Hospital-Cleveland Clinic, Cleveland, Ohio, USA.
J Intensive Care Med. 2025 Jan;40(1):54-59. doi: 10.1177/08850666241264774. Epub 2024 Jul 25.
The methicillin-resistant (MRSA) accounts for 20% to 40% of all hospital-acquired pneumonia (HAP) cases with mortality rates up to 55%. Prompt and accurate diagnosis is essential, especially in intensive care unit (ICU) patients. Nasal MRSA polymerase chain reaction (PCR) diagnostic utility evidence is conflicting in the literature for HAP due to a low number of HAP patients included in prior studies or due to the lack of high-yield gold standard cultures defined for comparisons. This was a retrospective cohort study conducted in a 65-bed medical ICU, and encompassing all adult patients admitted from January 2015 to March 2023 for HAP. Respiratory cultures included were those obtained by bronchoalveolar lavage or endotracheal suction within 7 days of nasal MRSA PCR testing. The study included 412 patients; 56.8% were males and 65% were Whites. The mean age was 60.5 years. Most patients (82.5%) underwent MRSA-PCR before intubation, and the average time between MRSA-PCR and lower respiratory cultures was 2.15 days. The diagnostic performance of nasal MRSA PCR in diagnosing HAP in the ICU yielded a sensitivity (Sen) of 47.83%, specificity (Sp) of 92.29%, positive predictive value (PPV) of 26.83%, and negative predictive value (NPV) of 96.77%. For nonventilator HAP (nv-HAP) cases sensitivity was at 50%, specificity 92.83%, PPV 28.57%, and NPV at 97.00%. In ventilator-acquired pneumonia (VAP-HAP), the corresponding values were 42.86%, 90.91%, 23.08%, and 96.15%, respectively. The nasal MRSA PCR shows a high NPV and low false negative rate, suggesting it is a reliable tool for ruling out MRSA HAP in ICU patients. Care should be taken into account for disease prevalence and clinical context, as these factors may influence test performance. Further validation through prospective large-sample studies utilizing high-yield lower respiratory tract cultures is necessary to confirm our findings.
耐甲氧西林金黄色葡萄球菌(MRSA)占所有医院获得性肺炎(HAP)病例的20%至40%,死亡率高达55%。及时准确的诊断至关重要,尤其是在重症监护病房(ICU)患者中。由于先前研究纳入的HAP患者数量较少,或者由于缺乏用于比较的高产金标准培养物,鼻腔MRSA聚合酶链反应(PCR)在HAP诊断中的效用证据在文献中存在冲突。这是一项在拥有65张床位的内科ICU中进行的回顾性队列研究,涵盖了2015年1月至2023年3月因HAP入院的所有成年患者。纳入的呼吸道培养物是在鼻腔MRSA PCR检测后7天内通过支气管肺泡灌洗或气管内抽吸获得的。该研究包括412名患者;56.8%为男性,65%为白人。平均年龄为60.5岁。大多数患者(82.5%)在插管前进行了MRSA-PCR,MRSA-PCR与下呼吸道培养之间的平均时间为2.15天。鼻腔MRSA PCR在ICU中诊断HAP的诊断性能产生的敏感性(Sen)为47.83%,特异性(Sp)为92.29%,阳性预测值(PPV)为26.83%,阴性预测值(NPV)为96.77%。对于非呼吸机相关性HAP(nv-HAP)病例,敏感性为50%,特异性为92.83%,PPV为28.57%,NPV为97.00%。在呼吸机相关性肺炎(VAP-HAP)中,相应的值分别为42.86%、90.91%、23.08%和96.15%。鼻腔MRSA PCR显示出高NPV和低假阴性率,表明它是排除ICU患者MRSA HAP的可靠工具。应考虑疾病患病率和临床背景,因为这些因素可能影响检测性能。需要通过使用高产下呼吸道培养物的前瞻性大样本研究进行进一步验证,以证实我们的发现。